Stoke Therapeutics, Inc. (STOK) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
Stoke Therapeutics, Inc. (STOK) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$41.93 MLiabilities$48.42 MNon-current liabilities$6.49 MEquity$345.55 MGross equity(calculated)$955.43 MCurrent assets$322.54 MAssets$393.97 MNon-current assets$71.43 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable securities - currentCash and cash equivalentsPrepaid expensesAccounts receivableOther current assetsInterest receivableMarketable securities - long-termProperty and equipment, netRestricted cash - long-termOperating right-of-use assetsAccrued and other current liabilitiesDeferred revenue - current portionAccounts payableDeferred revenue - net of current portionOther long-term liabilitiesAdditional paid-in capitalCommon stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,402,595 and 58,921,999 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive (loss) incomeCurrent liabilitiesCurrent liabilities$41.93 MAccrued and other current liabilitiesAccrued and other current liabilities$28.61 MDeferred revenue - current portionDeferred revenue - current portion$8.52 MLiabilitiesLiabilities$48.42 MAccounts payableAccounts payable$4.79 MNon-current liabilitiesNon-current liabilities$6.49 MEquityEquity$345.55 MDeferred revenue - net of current portionDeferred revenue - net of current portion$5.65 MOther long-term liabilitiesOther long-term liabilities$837.00 KGross equity (calculated)Gross equity(calculated)$955.43 MCurrent assetsCurrent assets$322.54 MMarketable securities - currentMarketable securities - current$182.81 MAssetsAssets$393.97 MCash and cash equivalentsCash and cash equivalents$110.00 MPrepaid expensesPrepaid expenses$14.69 MAccounts receivableAccounts receivable$7.18 MOther current assetsOther current assets$6.31 MInterest receivableInterest receivable$1.54 MAdditional paid-in capitalAdditional paid-in capital$955.42 MMarketable securities - long-termMarketable securities - long-term$61.50 MNon-current assetsNon-current assets$71.43 MProperty and equipment, netProperty and equipment, net$4.83 MRestricted cash - long-termRestricted cash - long-term$3.23 MOperating right-of-use assetsOperating right-of-use assets$1.87 MCommon stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,402,595 and 58,921,999 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectivelyCommon stock$6.00 KAccumulated deficitAccumulated deficit−$609.34 MAccumulated other comprehensive (loss) incomeAccumulated other comprehensive (loss) income−$542.00 K
Chart details

Stoke Therapeutics, Inc. (STOK) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
393,966,000 US dollars
Current assets
322,538,000 US dollars
Non-current assets
71,428,000 US dollars
Liabilities
48,419,000 US dollars
Current liabilities
41,930,000 US dollars
Non-current liabilities
6,489,000 US dollars
Equity
345,547,000 US dollars
Marketable securities - current
182,814,000 US dollars
Cash and cash equivalents
110,004,000 US dollars
Prepaid expenses
14,688,000 US dollars
Accounts receivable
7,179,000 US dollars
Other current assets
6,313,000 US dollars
Interest receivable
1,540,000 US dollars
Marketable securities - long-term
61,502,000 US dollars
Property and equipment, net
4,829,000 US dollars
Restricted cash - long-term
3,227,000 US dollars
Operating right-of-use assets
1,870,000 US dollars
Accrued and other current liabilities
28,613,000 US dollars
Deferred revenue - current portion
8,523,000 US dollars
Accounts payable
4,794,000 US dollars
Deferred revenue - net of current portion
5,652,000 US dollars
Other long-term liabilities
837,000 US dollars
Additional paid-in capital
955,419,000 US dollars
Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,402,595 and 58,921,999 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively
6,000 US dollars
Accumulated deficit
negative 609,336,000 US dollars
Accumulated other comprehensive (loss) income
negative 542,000 US dollars
Gross equity (calculated)
955,425,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Stoke Therapeutics, Inc. (STOK) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!